• First in Midwest

    Cardiologists at Beaumont Hospital, Royal Oak have performed the Midwest’s first implant of a device recently approved by the FDA for patients with non-valvular atrial fibrillation.

    The Watchman Left Atrial Appendage Closure implant is an alternative to long-term use of blood-thinning warfarin medication to reduce the risk of stroke.

    Read More
  • 94-year-old Dearborn Heights woman beats cancer and heart disease

    2014 was an eventful year for Lily Dudgeon of Dearborn Heights. The feisty, independent 94-year-old faced and beat the two biggest killers of humankind: first cancer, then heart disease.

    It all began in late 2013 when her son found her passed out, half-in and half-out of her car in the garage. He called 911.

    Read More
  • Beaumont, Royal Oak Heart & Vascular program among the best in the nation

    The Heart & Vascular program at Royal Oak is ranked among the top 25 in the nation and the top hospital in Michigan, according to the 2014-15 U.S. News & World Report “Best Hospitals.”

    Read More

Newsletters

For Patients
State of the Heart

For Physicians
Heart & Vascular Update

7 Tests for $70

Identify risk factors and help improve your heart health. Schedule a heart screening at the location nearest you, request a test online (select Heart and Vascular Screening) or contact the Appointment Center at 800-328-8542.

For Health Care Professionals:
Training and Education Opportunities                   

Centers for Innovation and Research (CIRC)

Continuing Medical Education (CME)

Fellowships

Facility Rental Guide

Specialty Spotlight

The WATCHMAN Left Atrial Appendage Closure Device is a first-of-its-kind, proven alternative to commonly-used blood thinner warfarin to prevent stoke in patients with atrial fibrillation or an abnormal heart beat. The WATCHMAN device is implanted into the heart to close off the left atrial appendage (LAA), a blind pouch of heart tissue where blood clots can form and then break off and travel in the blood stream to the brain and cause strokes. The device is inserted into the heart through a catheter placed into a vein in the leg during a one-time, minimally invasive procedure in a cardiac catheterization lab. By closing off the LAA, patient’s risk of stroke is reduced and it may probably over time allow them to stop taking warfarin.

Beaumont cardiologists performed the Midwest’s first commercial implant of the WATCHMAN device in March 2015. To make an appointment with a Beaumont cardiologist, call 800-633-7377.

 

Copyright © 2015 Beaumont Health System. All Rights Reserved. Privacy Policy | Site Map